Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-6160 and VRC HIV Env Trimer 4571 in Healthy Adults
NCT05828095Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of INO-6160 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness, Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Erythema and/or Induration and 10 more. Started Apr 2023; status: completed.
02
Drugs
INO-6160
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05828095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828095.